Sound of Science Podcast


Listen to Prof. Chloe Orkin and Dr. Perry Mohammed review the SOLAR data.

PM-GB-CBR-WCNT-230018 | January 2024

- -

UK National Webinar Recordings

PM-GB-CBR-VID-220008 | November 2022

PM-GB-CBR-VID-220005 | November 2022

PM-GB-CBR-VID-220006 | November 2022

PM-GB-CBR-VID-220007 | November 2022

PM-GB-CBR-VID-220010 | November 2022

PM-GB-CBR-VID-220004 | November 2022

PM-GB-CBR-VID-220009 | November 2022

REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-230017 | January 2024

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.